Chicko Rhonda M. reported option exercise involving 25,000 derivative units of Cyclerion Therapeutics, Inc. at $0.00 for $0 on Aug 14, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Aug 18, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
25,000Option to Purchase
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Aug 14, 2026Option exercise
Filed
Aug 18, 2026, 5:27 PM ET4-day reporting delay
Accession
0001193125-26-355721Code M · Transaction 3258
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 14, 2026Option exercise25,000$2.36$58,875Trade 3257
2 transaction rows in this filing. Joint filers share the same rows.

CYCN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CYCN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −10%1w ago −13%1d ago −5.1%
Returns since7d −2.7%30d90d180d1y

Footnotes in full

F1: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.